Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of CGEM is 30 and suggests 135% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell